Mohammed Rassool - Concepedia

Author

Mohammed Rassool

Also Known As

Chien-Ching Hung, Deborah Langat, Ive, Prudence, M Rassool, M. Rassool, Maphoshane Nchabeleng, Mario Camblart, Mohammed Rassool, Mohammed S Rassool, Mohammed S. Rassool

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

University of the Witwatersrand Helen Joseph Hospital University College London University of Cape Town London School of Hygiene & Tropical Medicine

About

Mohammed Rassool is an author at University of the Witwatersrand specializing in medicine, hiv, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	758
2	Nursing	2	2	326
3	Public Health	1	1	76
4	Social Sciences	1	1	76
5	Global Health	1	1	76

Mohammed Rassool

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis Bern-Thomas Nyang’wa, Catherine Berry, Emil Kazounis, New England Journal of Medicine	2022	318
Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial Ian Sanne, Catherine Orrell, Matthew P. Fox, The Lancet NursingAntiretroviral TherapyAdvanced Practice NurseTreatment And PreventionPatient Safety	2010	250
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial Conor Tweed, Rodney Dawson, Divan A. Burger, The Lancet Respiratory Medicine	2019	143
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial Ruth Goodall, Sarah Meredith, Andrew Nunn, The Lancet Pulmonary TuberculosisRifampicin-resistant TuberculosisTuberculosis PreventionTuberculosisPharmacotherapy	2022	134
Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial Robert S. Wallis, Sibuse Ginindza, Trevor Beattie, The Lancet Respiratory Medicine	2021	123
Prevention of HIV-1 Infection with Early Antiretroviral Therapy for the HPTN 052 Study Team* Myron S. Cohen, Ying Qing Chen, Marybeth McCauley, Hptn 052Early Antiretroviral TherapyTreatment And PreventionHuman RetrovirusAntiviral Therapy	2011	86
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial Bern-Thomas Nyang’wa, Catherine Berry, Emil Kazounis, The Lancet Respiratory Medicine	2023	79
Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/μl is associated with improved treatment outcomes in South Africa Matthew P. Fox, Ian Sanne, Francesca Conradie, AIDS	2010	78
Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial Rami Kantor, Laura Smeaton, Saran Vardhanabhuti, Clinical Infectious Diseases	2015	78
Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 update Jeremy Nel, Sipho Dlamini, Graeme Meintjes, Southern African Journal of HIV Medicine Social SciencesPreventive MedicineHiv/aids CounsellingMedical AnthropologyPublic Health	2020	76

Page 1